Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. (“G3”) and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC and Acutis Diagnostics Inc. G3’s 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million.
Read the full article: Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs //
Source: https://www.globenewswire.com/news-release/2026/07/31/3337078/0/en/profusa-announces-signing-of-option-agreement-for-the-acquisition-of-a-commercial-stage-diagnostics-company-g3-vision-labs.html?_gl=1*162lcus*_up*MQ..*_ga*MTAyNDg1NjA4Ny4xNzg1NjkxMjA5*_ga_B6167QB2TF*czE3ODU2OTEyMDgkbzEkZzAkdDE3ODU2OTEyMDgkajYwJGwwJGgxNzUwNTk4OTgw*_ga_ERWPGTJ5X8*czE3ODU2OTEyMDkkbzEkZzAkdDE3ODU2OTEyMDkkajYwJGwwJGgw